Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS
03:38am, Wednesday, 11'th Feb 2026
Allianz Asset Management GmbH acquired a new stake in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent
04:03pm, Friday, 06'th Feb 2026
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and A
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests
02:32pm, Tuesday, 03'rd Feb 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that esta
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide
09:03am, Tuesday, 03'rd Feb 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX B
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
01:22pm, Thursday, 29'th Jan 2026
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were
EXEL vs. EXAS: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 27'th Jan 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value investor
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
03:54am, Monday, 26'th Jan 2026
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were
Briacell Therap (NASDAQ:BCTX) versus Exact Sciences (NASDAQ:EXAS) Head-To-Head Survey
02:48am, Friday, 23'rd Jan 2026
Exact Sciences (NASDAQ: EXAS - Get Free Report) and Briacell Therap (NASDAQ: BCTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies b
Small-Cap Growth Without Dividends: What NUSC's 1.4 Beta Really Costs Investors
08:06am, Thursday, 22'nd Jan 2026
Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential.
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
05:15am, Thursday, 22'nd Jan 2026
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractor
Pre-Market Stock Futures: Futures are trading dramatically lower as we start the holiday-shortened trading week, following yesterday's MLK remembrance day. The futures downdraft this morning is being
Exact Sciences Corporation $EXAS Stock Position Boosted by Massachusetts Financial Services Co. MA
07:33am, Tuesday, 20'th Jan 2026
Massachusetts Financial Services Co. MA grew its stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 31.7% during the third quarter, according to its most recent filing with the Securities
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS).
Should You Continue to Hold EXAS Stock in Your Portfolio Now?
08:35am, Tuesday, 30'th Dec 2025
Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.
